It is rare for a study to address immediate metabolic change in pre-eclamptic pregnancy. Our aim is to study the ante-partum and post-partum metabolic markers in pre-eclampsia. A total of 33 pre-eclamptic and 200 uncomplicated women with singleton pregnancies were recruited for the prospective research. Immediately ante-partum and 24-48 h postpartum venous blood samples were collected for the analysis of metabolic markers. In the pre-eclamptic group, the ante-partum fasting glucose, fasting insulin, triglyceride and free fatty acid levels were found to be higher than in the control group; however, ante-partum high-density lipoprotein level was lower. Interestingly, fasting glucose and insulin levels decreased by 24-48 h post-partum in both groups and no significant differences were found.
Introduction
Pre-eclampsia is a common multisystem pregnancy disorder in which diagnosis is based on hypertension and proteinuria, affecting 3-5% of all pregnancies. Pre-eclampsia generally occurs de novo in late pregnancy, and severe cases constitute a serious threat to the mother and the fetus. This disorder is a major cause of prenatal and maternal morbidity and mortality worldwide. [1] [2] [3] Pre-eclampsia is also associated with an increased risk of cardiovascular disease and type II diabetes later in life for the mother. [4] [5] [6] [7] [8] The aetiology of pre-eclampsia is still unknown and multiple factors are implicated in its pathogenesis. Metabolic syndrome, especially insulin resistance, and pre-eclampsia are well examined in previous research. [9] [10] [11] Insulin resistance is common in pregnancy, as are aberrant lipid metabolism, higher fasting glucose level and increased insulin secretion. 12 These metabolic changes are likely to have evolved to meet the metabolic demands of a growing fetus, but these changes are exaggerated in pre-eclampsia. 13 The relationship between variables of metabolic syndrome and pre-eclampsia after delivery has been studied by many researchers. 10, 14 Most studies have assessed the 'peak' stage but with less attention to the post-partum stage. It has been reported that markers of metabolic syndrome reach their peaks in the third trimester and rapidly decrease after delivery. 15 We are interested in the following question that has been rarely asked in previous studies: how rapidly can metabolic markers change and, for pre-eclampsia in particular, what are the glucose and lipid profile characteristics within 24-48 h post-partum? 16 Our aim is to investigate how the ante-partum (third trimester) variables of metabolic syndrome change in pre-eclamptic patients and uncomplicated women.
Materials and methods
Case selection and sampling A total of 33 women with singleton pregnancies were selected for a prospective cohort study of preeclampsia at the Department of Obstetrics of the Guangdong Women and Children's Hospital and Health Institute between August, 2008 and April, 2009. Women with concomitant disease, such as diabetes or a history of gestational diabetes, chronic hypertension and kidney disease or coagulation disorders were excluded. The criterion to confirm a diagnosis of pre-eclampsia was the presence of proteinuric hypertension (new onset of hypertension and that of proteinuria at 420 weeks of gestation). Hypertension is defined as systolic blood pressure of, at least, 140 mm Hg and diastolic blood pressure of 90 mm Hg on, at least, two occasions; the measurements should be, at least, 4 h (but not 47 days) apart. Proteinuria is defined primarily as a concentration of X30 mg 100 ml À1 (1 þ ) in, at least, two random urine specimens that were collected at least X4 h apart (but within a 7-day interval) or 0.3 g in a 24-h period. We also included 200 normotensive, non-proteinuric women as a normal control group; these women were recruited at the time of admission to the hospital. Informed consent to participate in the study was obtained from the patients or the patients' relatives (husbands or parents) after explaining the innocuous nature of the investigations being conducted. Approval for the study was obtained from the local hospital ethics committee.
Demographic variables were recorded and baseline blood pressure was acquired using questionnaire according to the pre-pregnancy physical examination. We considered the blood pressure in the first trimester to be the 'baseline blood pressure' if the patient did not know her pre-pregnancy blood pressure (Table 1) . At examination, the range of gestational age was 33-39 (median 36) weeks in the pre-eclamptic group and 38-40 (median 38) weeks in the control group. The two groups had different amounts of weight gain during pregnancy (15.04 ± 6.64 kg pre-eclamptic vs 12.2 ± 4.84 kg control; Po0.001), though the pre-eclamptic group had similar pre-pregnancy body mass indices (BMIs) when compared with the control group. Baseline blood pressure was significantly higher (124/ 76 mm Hg on average vs 111/68 mm Hg on average, Po0.001) in pre-eclamptic patients during the pre-gravid period or in first trimester. Insulin resistance was calculated using the homeostasis model assessment ratio (HOMA-IR). Blood samples were collected after patients had fasted for 8-10 h for the analysis of lipids (total cholesterol, highdensity lipoproteins (HDLs), low-density lipoproteins (LDLs), free fatty acids (FFAs) and triglycerides (TGs)), apolipoprotein A1 and apolipoprotein B, fasting insulin (F-insulin) and fasting glucose.
Data analysis
Normally distributed data are given as mean±s.d. values and non-normally distributed data as medians with inter-quartile ranges (25-75th percentiles). Student's t-test and the Mann-Whitney U test were used to assess the differences between the groups. P-values o0.05 were considered statistically significant. Table 2 shows the ante-partum variables in both groups. Fasting glucose and insulin levels were found to be higher in the pre-eclamptic group (P ¼ 0.006 and 0.005, respectively). Accordingly, the HOMA-IR in the pre-eclamptic group is obviously higher than that in the control group (1.74 ± 1.061 vs 2.28 ± 1.64, P ¼ 0.002). With regard to ante-partum lipid metabolism, total cholesterol, LDL and apolipoprotein levels were similar between the groups. The concentrations of TGs and FFAs were all higher in women with pre-eclampsia and levels of HDL were diminished compared with the control group. Table 3 shows the post-partum variables. Both F-insulin and F-glucose levels decreased rapidly by 24-48 h post-partum, which resulted in resolution of any significant difference between the two groups in HOMA-IR (0.9 ± 0.86 vs 1.10 ± 1.02, P ¼ 0.31). The markers of metabolic syndrome in the pre-eclamptic group were still significantly different from that of the control group with the exceptions of post-partum total cholesterol, LDL and Ante-partum and post-partum markers in pre-eclampsia Q Lei et al apolipoprotein A1. We found that the pre-eclamptic group had lower concentrations of HDL (1.30 ± 0.31 vs 1.46±0.34 mmol l À1 , P ¼ 0.02), which is a known protective factor of cardiovascular disease. Higher TG (3.23 ± 3.09 vs 2.29 ± 0.76 mmol l À1 , Po0.001), higher FFA (670.67 ± 336.0 vs 417.77 ± 119.87 mEg l À1 , P ¼ 0.02) and higher apolipoprotein B (1.23±0.31 vs 1.11 ± 0.25 g l À1 , P ¼ 0.01) levels were found in the pre-eclamptic group when compared with the control group.
Results

Ante-partum variables
Post-partum variables
Comparison of ante-partum and post-partum laboratory value of both groups Figure 1 shows the comparison of ante-partum and post-partum laboratory values in the control group.
The mean concentration of F-insulin had decreased by 48% after delivery (Po0.005), whereas no significant difference was found in F-glucose level (P ¼ 0.81). The lipid profile shows that every item, except HDL, was significantly decreased. The mean concentrations of total cholesterol, LDL, TG, apolipoprotein A1 and apolipoprotein B had decreased by 7, 7, 19, 18 and 7%, respectively. There was no significant change in HDL level. Figure 2 shows the comparison of ante-partum and post-partum laboratory values in the preeclamptic group. There was no significant difference in F-glucose level (P ¼ 0.13), but F-insulin level had decreased by 53% after delivery (Po0.005), which is similar to the control group. The lipid profile shows that all variables tested, except apolipoprotein A1, had no significant change before and after delivery. These variables include cholesterol (P ¼ 0.31), HDL (P ¼ 0.99), LDL (P ¼ 0.42), TG (P ¼ 0.35), apolipoprotein B (P ¼ 0.61) and FFAs (P ¼ 0.57), which is a quite different pattern than seen in the control group. Figure 3 presents ante-partum and 24-48-h postpartum serum FFA levels in the two groups. Concentrations in women with pre-eclampsia were statistically higher than those of normal parturient before delivery (median: pre-eclampsia 754.5 mEg l À1 (383.5-1125. 5 inter-quartile range); control 496.6 mEg l À1 (318.3-674.9 inter-quartile range); Po 0.001). Free fatty acids decreased by 24-48 h post-partum in both groups (P ¼ 0.57, pre-eclampsia; and Po0.05, control). Serum FFA levels at 24-48 h post-partum remained higher in the pre-eclamptic group relative to uncomplicated pregnancies (median: pre-eclamptic 670.67 mEg l À1 (334.67-1006.67 inter-quartile range); control 417.77 mEg l À1 (297.96-537.58 inter-quartile range); P ¼ 0.034).
Discussion
Pre-eclampsia and insulin resistance Normal pregnancy is characterized by increased maternal insulin release in late pregnancy. These metabolic changes are likely to have evolved to meet the metabolic demands of the growing fetus and will change rapidly in normal women after delivery. 16 The reasons for this insulin resistance in normal pregnancy are not well understood, although it has been suggested that placental hormones, such as lactogen, cortisol, progesterone and oestrogen, and tumour necrosis factor may be responsible. 17 It is thought that these metabolic changes are exaggerated in pre-eclampsia. To eliminate the effect of pre-pregnancy weight on metabolic status and insulin resistance, women with pre-pregnancy BMI values similar to those of pre-eclamptic women were chosen to serve as a control group.
We found that ante-partum fasting glucose and insulin levels are higher in women with preeclampsia, which is in agreement with previous Ante-partum and post-partum markers in pre-eclampsia Q Lei et al studies. [18] [19] [20] The ante-partum HOMA-IR, which is a favourable index for evaluating insulin sensitivity, is obviously higher in the pre-eclamptic group than in the control group, indicating that these patients have more serious insulin resistance, at least, in the third trimester. We studied the metabolic markers of women with pre-eclampsia and pregnant women without any complication at 24-48 h after delivery and observed that the insulin secretion in both groups decreased by almost 50% after delivery. Finally, no significant difference was found between the two groups (P ¼ 0.37), and there was no significant difference between the groups with regard to HOMA-IR (P ¼ 0.31). The removal of the placenta, which secretes hormones to resist insulin activity, is mainly responsible. Though ante-partum fasting insulin level was higher in pre-eclamptic patients, no significant difference was found between the pre-eclamptic group and the control group, at least, 24-48 h after delivery. It has been proven that insulin resistance is one of the components of the metabolic syndrome present in pre-eclamptic women, [21] [22] [23] but we assume that hyperinsulinemia has a less important role in the genesis and development of pre-eclampsia. 
Pre-eclampsia and dyslipidemia
It was reported that hyperinsulinemia may be a coexisting condition in women who have previously developed pre-eclampsia. 24 To our surprise, dyslipidemia, but not higher fasting insulin level, was observed in the pre-eclamptic post-partum period (24-48 h). Altered lipids, especially increased FFAs and increased TGs, may have an important role in the endothelial cell dysfunction seen in pre-eclampsia. Our data demonstrate that circulating TGs and FFAs are markedly elevated in women with pre-eclampsia ante-partum, which is in accordance with the fact that weight gain during pregnancy was 23% higher in these women than in women with uncomplicated pregnancies (15.04±6.64 kg vs 12.2±4.84 kg, Po0.001). We speculated that dyslipidemia may have an important role in the pathophysiology of Preeclampsia. Ray et al. 25 observed that there is a consistent positive association between elevated maternal TG levels and the risk of pre-eclampsia. Additional research indicates that pre-eclamptic women have higher circulating FFAs. 26 Although hemoconcentration might contribute to increased serum lipid concentrations in pre-eclampsia, in this study, it is unlikely to explain a major portion of the significant differences observed. Pre-eclamptic women have a higher molar ratio of FFAs to albumin compared with women with normal pregnancies. This leads to enhanced endothelial cell uptake of FFAs that are further esterified into TGs. 27 Accumulation of TGs, a well-known feature of pre-eclampsia, could interfere with the function of endothelial cells.
The interplay between dyslipidemia and insulin sensitivity in pre-eclampsia may be regulated by other factors, such as placental hormones. Other examples of this phenomenon include adipokines, adiponectin and adipocyte fatty acid-binding protein, the concentrations of which are increased in pre-eclampsia. 28, 29 Uterine hypoperfusion, which is often seen in pre-eclampsia, may lead to elevated production of lipoxygenase products, an alternative pathway of arachidonic acid metabolism. These lipoxygenase products, called leukotrienes, could be responsible for the inhibition of prostacyclin production, hypertension, and the increased endothelial permeability seen in pre-eclampsia.
In addition, the expression of a potent inflammatory mediator, interleukin-8, by the vascular smooth muscle of pre-eclamptic women is increased. Furthermore, interleukin-8 production was stimulated when placental smooth muscle cells were exposed to linoleic acid under conditions of oxidative stress. 30 Serum TG levels decreased strikingly by 24-48 h post-partum in both groups and were strongly dependent on the initial ante-partum serum concentration.
In women with pre-eclampsia, we also found that TG concentrations post-partum remained higher than in normal controls. Higher insulin sensitivity was associated with higher HDL level. The concentrations of TGs and FFAs, although decreased, were still statistically significant after delivery. Unexpectedly, we found no difference between the control and pre-eclamptic groups in ante-partum/post-partum fasting total cholesterol concentrations, which might be due to the limited size of the study groups. This finding requires further investigation.
Finally, some researchers have focused on lipid metabolism before 20 weeks of gestation and found that hypertriglyceridemic dyslipidemia is associated with the risk of developing early onset pre-eclampsia. 31 Other studies have reported that women with pre-eclampsia exhibit dyslipidaemia in the 6-13 months following delivery. 32 Our results in women with and without pre-eclampsia in the 24-48-h period after delivery can be considered a supplement to a profile of the initial follow-up of lipid metabolism surrounding pregnancy and delivery.
Pre-eclampsia and metabolic syndrome The components of metabolic syndrome (increased visceral fat, blood pressure and dyslipidemia) have been shown to be of special interest. Pre-eclampsia has many characteristics similar to those of metabolic syndrome. [33] [34] [35] The observation that blood pressure was significantly higher (124/76 mm Hg on average vs 111/ 68 mm Hg on average, Po0.001) during the pregravid period or in first trimester is similar to findings of previous studies. 36 Most studies have not taken into account pre-gravid BMI that is associated both with increased insulin resistance and with pre-eclampsia. In fact, pre-gravid BMI is another component of the metabolic syndrome that has been shown to be increased before a preeclamptic pregnancy. 37 We analysed increasing pre-gravid obesity (higher BMI) and unfavourable lipid status surrounding pregnancy and delivery in the form of increased triglyceride and FFA levels. Together with high blood pressure, these two factors seem to be related to other metabolic changes. To eliminate the effect of weight on metabolism, the pre-eclamptic patients and controls enroled in our study were characterized by the similarity in their pre-gravid BMI, and there was no significant difference in age. Under these conditions, we could Ante-partum and post-partum markers in pre-eclampsia Q Lei et al characterize the metabolic syndrome found in preeclamptic patients as an abnormal status; they have not only higher baseline blood pressure, but also dyslipidemia and increased weight gain. All our observations increase our suspicion that women who develop pre-eclampsia may already have insulin resistance. This insulin resistance may last for a long time and may even be a risk factor for cardiovascular disease in long-term follow-up. 14, 38 Finally, insulin resistance seems to be more common in women who are destined to develop pre-eclampsia months before clinically evident disease is detected. We did not determine the preeclamptic patients' glucose or lipid metabolism before the clinical syndrome emerged, and we acknowledge that the number of patients was limited. Maternal plasma lipid concentrations in early pregnancy and 6 weeks after delivery are more favourable, and these kinds of examination will be performed in the near future.
Conclusion
In conclusion, compared with normal pregnant women with similar pre-gravid BMI with no significant difference in age, we observed that preeclamptic women have higher baseline blood pressure and increased weight gain during pregnancy. Fasting glucose and insulin levels are higher in preeclamptic women before delivery, but after delivery, no difference exists between the two groups. Dyslipidemia lasts from the ante-partum to the immediate post-partum period in pre-eclamptic women in the form of increased triglyceride, FFA and decreased HDL levels. We speculate that woman with dyslipidemia and higher baseline blood pressure tend to gain more weight and develop into preeclamptic patients during pregnancy. It is possible that these interactions may have been initiated before pregnancy and may contribute to endothelial cell dysfunction, not only in pre-eclampsia, but also in the onset of cardiovascular disease or metabolic syndrome later in life. The development of preeclampsia may be a 'marker' of possible future cardiovascular or metabolic disease.
